• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    BioOptics Stock Watch
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Chromadex Corp CS (NQ: CDXC )

    5.860 +2.370 (+67.91%)
    Streaming Delayed Price Updated: 4:00 PM EDT, Nov 1, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 37,879,817
    Open 4.120
    Bid (Size) 5.730 (47)
    Ask (Size) 5.760 (3)
    Prev. Close 3.490
    Today's Range 3.830 - 5.980
    52wk Range 1.320 - 5.980
    Shares Outstanding 68,196,526
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    Crude Oil Moves Higher; Apple Shares Slide After Q4 Results
    Via Benzinga
    Exposures Fossil Fuels
    12 Health Care Stocks Moving In Friday's Intraday Session
    Via Benzinga

    Performance

    YTD
    +309.79%
    +309.79%
    1 Month
    +68.88%
    +68.88%
    3 Month
    +111.55%
    +111.55%
    6 Month
    +55.03%
    +55.03%
    1 Year
    +315.60%
    +315.60%

    More News

    Read More
    Nasdaq Surges Over 200 Points; Amazon Shares Jump After Strong Results
    Via Benzinga
    Dow Jumps 400 Points; US Adds 12,000 Jobs In October
    Via Benzinga
    Topics Stocks
    Exposures US Equities
    12 Health Care Stocks Moving In Friday's Pre-Market Session
    Via Benzinga
    Insights into ChromaDex's Upcoming Earnings
    Via Benzinga
    CDXC Stock Earnings: ChromaDex Misses Revenue for Q2 2024
    Via InvestorPlace
    12 Health Care Stocks Moving In Thursday's After-Market Session
    Via Benzinga
    ChromaDex Corporation Reports Third Quarter 2024 Financial Results
    From ChromaDex Corporation
    Via Business Wire
    ChromaDex to Report Third Quarter 2024 Financial Results on Thursday, October 31, 2024
    From ChromaDex Corporation
    Via Business Wire
    ChromaDex to Report Third Quarter 2024 Financial Results on Thursday, October 31, 2024
    From ChromaDex Corporation
    Via Business Wire
    ChromaDex to Participate in the 17th Annual LD Micro Main Event
    From ChromaDex Corporation
    Via Business Wire
    Yasmeen Nkrumah-Elie, Ph.D., Global Director of External Research at ChromaDex, Honored with the Trailblazing Woman Award by Radicle Science and Council for Responsible Nutrition (CRN)
    From ChromaDex Corporation
    Via Business Wire
    ChromaDex to Participate in a Fireside Chat at the Lytham Partners Fall 2024 Investor Conference
    From ChromaDex Corporation
    Via Business Wire
    ChromaDex Appoints Ozan Pamir as Chief Financial Officer
    From ChromaDex Corporation
    Via Business Wire
    ChromaDex Announces Expansion of Pharmaceutical-Grade Niagen® IV and Injection Offerings to Additional Leading Wellness Clinics
    From ChromaDex Corporation
    Via Business Wire
    ChromaDex Celebrates 25 Years of Innovation and Pioneering NAD+ Research for Healthy Aging Solutions
    From ChromaDex Corporation
    Via Business Wire
    ChromaDex to Participate in Renmark’s Virtual Non-Deal Roadshow Series On Thursday, August 29, 2024
    From ChromaDex Corporation
    Via Business Wire
    ChromaDex Secures U.S. Patent for the Composition of Matter of Salt Forms of NMNH (Dihydronicotinamide Mononucleotide), a Precursor to NAD+
    From ChromaDex Corporation
    Via Business Wire
    ChromaDex Corporation Reports Second Quarter 2024 Financial Results
    From ChromaDex Corporation
    Via Business Wire
    ChromaDex to Present at Canaccord Genuity’s 44th Annual Growth Conference
    From ChromaDex Corporation
    Via Business Wire
    ChromaDex to Report Second Quarter 2024 Financial Results on Wednesday, August 7, 2024
    From ChromaDex Corporation
    Via Business Wire
    ChromaDex Launches Niagen+ NAD+ Test Kit Available Exclusively to Health Care Practitioners (HCPs)
    From ChromaDex Corporation
    Via Business Wire
    ChromaDex Appoints Carlos Lopez as Senior Vice President, General Counsel
    From ChromaDex Corporation
    Via Business Wire
    ChromaDex Announces Pharmaceutical-Grade Intravenous and Injectable Niagen® Will Debut at Leading Wellness Clinics in August
    From ChromaDex Corporation
    Via Business Wire
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.